MotherToBaby

Medications and More during pregnancy and breastfeeding

Buscar

866.626.6847

Buprenorphine

Selected References:

  • American College of Obstetricians and Gynecologists (ACOG). 2017. Reaffirmed October 2021. Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol 130: e81-e94.
  • Anderson JM, et al. 2020. Prenatal exposure to methadone or buprenorphine and long-term outcomes: a meta-analysis. Early Human Development Apr;143:104997.
  • Austin A, et al. 2021. Prenatal use of medication for opioid use disorder and other prescription opioids in cases of neonatal opioid withdrawal syndrome: North Carolina Medicaid, 2016-2018. Am J Public Health Sep;111(9):1682-1685.
  • Chao CR, et al. 2023. Effects of medications for opioid use disorder (MOUD) on fetal brain and cranial measurements. Neurotoxicol Teratol: 97:107177.
  • Conradt E, et al. 2019. Prenatal opioid exposure: Neurodevelopmental consequences and future research priorities. Pediatrics 144(3):e20190128.
  • Coulson C, et al. 2021. Association of maternal buprenorphine or methadone dose with fetal growth indices and neonatal abstinence syndrome. Am J Perinatol 38(01):028-036.
  • Dorey A, et al. 2019. Possible buprenorphine toxicity in a breastfeeding neonate. Clin Toxicol. 57:889-890.
  • Gawronski KM, et al. 2014. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. SAGE Open Medicine 2: 2050312114530282.
  • Handal M, et al. 2019. Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway. Pharmacol Res Perspect 7(5):e00501.
  • Ito, S. 2018. Opioids in breast milk: Pharmacokinetic principles and clinical implications. J Clin Pharmacol 58 Suppl 10:S151-S163.
  • Jansson LM, et al. 2017. Maternal buprenorphine treatment and infant outcome. Drug Alcohol Depen. 180 (November):56-61.
  • Jansson LM, et al. 2016. Maternal buprenorphine maintenance and lactation. J Hum Lact. 32:675-81.
  • Jones HE, et al. 2012. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 107 (Suppl. 1): 5–27.
  • Jones JD, et al. 2012. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 125(1-2): 8–18.
  • Hemmati Z, et al. 2022. Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: A systematic review and meta-analysis. Neurosci Biobehav Rev: 136:104601.
  • Kacinko S, et al. 2008. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 84(5):604-12.
  • Kallenbach K, et al. 2012. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 107 (Suppl. 1):45-52.
  • Kanervo, MM, et al. 2023. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. Acta Obstet Gynecol Scand: 102: 313-322.
  • Kinsella M, et al. 2022. Buprenorphine Compared with Methadone in Pregnancy: A Systematic Review and Meta-Analysis. Subst Use Misuse: 57(9):1400-1416.
  • Kocherlakota P. 2014. Neonatal Abstinence Syndrome. Pediatrics 134(2):e547-61.
  • Krans EE, et al. 2021. Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction: 116(12):3504-3514.
  • Kumar N, et al. 2021. Impact of opioid maintenance treatment during pregnancy on neonatal birth weight and head circumference. J Neonatal Perinatal Med: 14(4):475-484.
  • Nelson LF, et al. 2020. Cognitive outcomes of young children after prenatal exposure to medications for opioid use disorder: a systematic review and meta-analysis. JAMA Netw Open Mar 2;3(3):e201195.
  • Reece-Stremtan S, Marinelli KA. 2015. ABM Clinical Protocol #21: Guidelines for breastfeeding and substance use or substance use disorder, Revised 2015. Breastfeed Med 10(3):135-141.
  • Ordean A, Tubman-Broeren M. 2023. Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature. Pathophysiology: 30(1):27-36.
  • Schuckit MA. 2016. Treatment of opioid-use disorders. N Engl J.Med. 375:357–68.
  • Soyka M, 2013. Buprenorphine use in pregnant opioid users: a critical review. CNS Drugs 27(8):653-662.
  • Staszewski CL, et al. 2020. Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies. J Perinat Med Sep 25;48(7):677-680.
  • Suarez EA, et al. 2022. Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. N Engl J Med: 387(22):2033-2044.
  • Sundelin-Wahlsten V, Sarman I. 2013. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediat 102(5): 544-549.
  • Wiegand SL, et al. 2015. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol. 125(2):363-8.

MotherToBaby cuenta con el apoyo de la Administración de Recursos y Servicios de Salud (HRSA) del Departamento de Salud y Servicios Humanos de los Estados Unidos (HHS) como parte de una adjudicación por un total de $6,000,000 con cero porcentaje financiado con fuentes no gubernamentales. Los contenidos son los del autor/es y no representan necesariamente los puntos de vista oficiales de, ni un respaldo, por HRSA, HHS o el Gobierno de los Estados Unidos.